Financial Shenanigans

Financial Shenanigans — Molina Healthcare, Inc. (MOH)

Forensic verdict: Watch (score 36/100). Molina's books are, on the evidence, a broadly faithful picture of a low-margin government-payer insurer — clean auditor opinion, effective internal controls, no restatement, and a board that let executive incentives pay zero in 2025 when results disappointed. But two linked, underwriteable threads keep this above the "Clean" band. First, reported earnings in FY2022–FY2024 were quietly cushioned by a growing reserve release: favorable prior-year medical-claims development climbed to $675 million in 2024 — roughly 42% of pre-tax income — then collapsed to $98 million in 2025 as the medical-cost cycle turned [1]. Second, operating cash flow is float-driven, not earned: it swung from +$2.1 billion (2021) to −$535 million (2025) on the timing of government settlements, so CFO is a poor proxy for profit in either direction [2]. Neither is manipulation; both are reasons to discount headline trends, not the integrity of the statements.

This is a forensic risk read, not a fraud accusation. Molina has no current restatement, SEC enforcement action, auditor change, or material-weakness finding in the record reviewed.

Sources: derived from reported financials, FY2021–FY2025 10-Ks — income, cash-flow and reserve notes [3]; [4].

The core question: are the numbers faithful?

Largely yes — with two interpretive caveats a PM must price in. Molina is a Medicaid/Medicare/Marketplace insurer whose entire income statement turns on one estimate: the IBNP liability (claims incurred but not yet paid), $3,211 million of the $4,887 million medical-claims reserve at year-end 2025, and the only Critical Audit Matter in the audit report [5]. Because a one- or two-point move in completion factors moves the reserve by hundreds of millions, the honest forensic posture is: the statements are credible and well-controlled, but headline margin and cash-flow trends are noisier than they look, and both were running with the wind at management's back through 2024.

The FY2025 result is the stress test, and Molina passed it the right way: it reported the full damage. Consolidated medical care ratio (MCR) rose 260 basis points to 91.7%, operating income halved to $781 million, and net income fell 60% to $472 million — taken to the income statement in the period, not deferred [6].

Earnings quality — the reserve cushion is the whole story

Takeaway: Molina did not hide the 2025 loss, but it did lean on a shrinking reserve cushion to smooth 2022–2024. For a health insurer, "favorable prior-year development" — booking medical costs lower than originally reserved — is the single largest earnings-quality lever. Molina's favorable development grew steadily as a share of medical costs and then cratered.

Source: Medical Claims and Benefits Payable roll-forwards, FY2021/FY2022/FY2025 10-Ks, Note 10 — "Components of medical care costs related to: Prior years" [7]; [8].

The pattern is textbook EM6 (income smoothing): a reserve "margin for adverse deviation" that built up in benign cost years and was released back into income. Favorable development reached $675 million in 2024 — about 42% of the $1,589 million pre-tax income [9]. In 2025 it fell to $98 million, and within that the Marketplace segment swung to unfavorable development of $61 million — the first sign that prior reserves were not conservative enough for that book [10]. Management's mitigant is real and disclosed: minimum-MLR floors and medical-cost corridors absorbed part of the swing, so the development was "ultimately not material to our consolidated MCR" [11].

The mirror image is the MCR trend. Reported MCR sat in a tight 88.0%–89.1% band from 2021 to 2024 while the cushion was being released; it broke out to 91.7% in 2025 when the release stopped and utilization spiked. The most violent move is Marketplace, where MCR jumped from 75.4% to 90.6% in a single year on mispriced acuity, Special-Enrollment members, and the newly acquired ConnectiCare book [12].

Source: MD&A consolidated MCR, FY2022/FY2023/FY2025 10-Ks [13]; [14].

Clean tests on the rest of the earnings line. Several earnings-quality probes come back negative, and that matters for credibility:

• Revenue timing (EM1) — clean. Premium revenue is recognized as coverage is provided; retroactive Medicaid rate changes and risk-corridor estimates are booked through "amounts due government agencies," not pulled forward [15]. Days-sales-outstanding is stable near 28–33 days across five years.
• One-time income props (EM3) — clean. Operating income fell; it was not flattered by gains. Investment income actually declined to $420 million in 2025 and is a modest, disclosed contributor [16].
• Cost capitalization (EM4) — clean. Capex is trivial at $101 million (0.2% of revenue) and is exceeded by $195 million of depreciation and amortization; there is no soft-asset balloon hiding operating costs [17].
• Hidden losses / under-reserving (EM5) — clean for 2025. The company absorbed the full MCR hit rather than deferring it; the down year is on the page.

The one earnings item to flag beyond EM6 is EM7 (big baths): a $208 million ($2.72/share) real-estate/right-of-use impairment in Q4 2022 tied to the remote-work footprint reduction [18]. It is legitimate, but it — like a Q1 2026 Medicare intangible write-down — is added back to the adjusted-EPS pay metric, which ties earnings quality directly to metric hygiene below.

Cash-flow quality — name the mechanism, and it is float

Takeaway: do not read Molina's operating cash flow as cash earnings in either direction. CFO is dominated by the timing of two liabilities an insurer carries — medical claims payable and "amounts due government agencies" (MLR rebates, risk corridors, risk-transfer). When those build, CFO prints far above net income; when they unwind, CFO goes negative even in a profitable year.

Source: Consolidated Statements of Cash Flows, FY2021/FY2022/FY2025 10-Ks [19]; [20].

The 2021 high (CFO of 3.2× net income) was a float build: "amounts due government agencies" alone contributed +$1,046 million of operating cash that year [21]. The 2025 low is the same lever in reverse. The bridge below decomposes the −$535 million: a profitable $472 million of net income was overwhelmed by −$591 million of government-settlement paybacks, −$132 million as claims payable shrank, −$221 million of payables, and −$201 million of cash taxes [22].

Source: FY2025 10-K Consolidated Statements of Cash Flows, operating section [23].

Within the cash-flow taxonomy:

• CF1 (financing inflows dressed as operating) — clean. Molina is an insurer with no receivables securitization or factoring; financing flows (a $850 million note issue in November 2025, $1.1 billion of facility draws fully repaid) sit in the financing section [24].
• CF2 (operating outflows pushed to investing) — clean. With capex at $101 million there is nothing material to reclassify.
• CF3 (CFO inflated by acquisitions) — watch, low. Molina is a serial acquirer; the ConnectiCare deal (closed February 2025, $350 million) added $379 million of medical-claims-payable float to the balance sheet that is netted out of operating working-capital changes, while the $245 million cash cost sits in investing [25]. Acquisition-adjusted free cash flow (CFO − capex − acquisitions) was −$881 million in 2025.
• CF4 (CFO from unsustainable activities) — yellow, high. This is the headline cash finding: CFO's level is set by government-payment timing, not by repeatable cash generation, and 2021–2024 CFO over-stated the durable cash the business throws off.

Metric hygiene — non-GAAP and the balance sheet

Takeaway: the non-GAAP adjustments are modest and well-disclosed, but they are the pay metric, and the "one-time" add-backs recur because Molina acquires every year. Management's headline profit figure is adjusted net income / adjusted EPS, and it is the basis for 80% of the short-term bonus and all multi-year PSUs [26]. The 2025 bridge adds back $91 million of intangible amortization and $55 million of "acquisition-related expenses," lifting GAAP net income of $472 million ($8.92/share) to adjusted $584 million ($11.03/share) — a 24% gap [27].

Source: FY2025 10-K income statement and 2026 Proxy pay-versus-performance / reconciliation tables [28]; [29].

The KM1 caveat is recurrence: "acquisition-related expenses" and acquired-intangible amortization are excluded as non-indicative, yet Molina has closed a deal nearly every year (Magellan/AgeWell 2020, Affinity 2021, AlohaCare/Cigna-TX 2022, My Choice Wisconsin 2023, Bright Health California 2024, ConnectiCare 2025), so these add-backs are a structural, recurring cost of the growth model [30]. The mitigants: the dollar add-back is small versus a $45 billion revenue base, it fully reconciles to GAAP, and the gap optically widened to 24% in 2025 only because the GAAP denominator collapsed — the adjustments themselves were stable.

KM2 (balance-sheet metric distortion) — yellow, low. Days-in-claims-payable, DSO, and goodwill/total-assets are all stable, so there is no metric being quietly redefined. The genuine balance-sheet signal is rising leverage and a covenant accommodation: long-term debt grew to $3,766 million (a fresh $850 million of 6.500% notes due 2031), and in February 2026 Molina amended its credit agreement to temporarily cut the minimum interest-coverage covenant from 3.0× to 1.75× for 2026 — a disclosed sign that earnings pressure is bumping against the capital structure, against a 60% maximum debt-to-capital limit (65% post-acquisition) [31].

Breeding ground — governance dampens, rather than amplifies, the flags

Takeaway: the governance environment makes accounting abuse less likely, not more. The founder-family era — and the related-party-revenue questions that came with it a decade-plus ago — ended when the Molina brothers departed in 2017. Today the structure is investor-friendly: an independent chairman (Dale Wolf) and an all-independent board except the CEO, a long-tenured but standard auditor in Ernst & Young, an unqualified opinion on both the financials and internal control over financial reporting dated February 2026, and policies banning hedging and pledging of stock plus a clawback [32]; [33].

The strongest dampener is that pay-for-performance actually bit in 2025: with adjusted EPS at $11.03 against a $22.05 bonus threshold, the compensation committee awarded no short-term cash bonus, the 2023 PSUs were forfeited in full, and the large CEO/CFO special retention grants (which require $36 of adjusted EPS in 2027) are expected to vest at $0 [34]. A management team willing to take zero in a bad year is not the profile of one straining to manufacture the number.

The one real governance blemish is a failed say-on-pay vote at the April 2025 meeting — only 40% support — but the substance was investor objection to those 2024 special grants (now likely worthless), not to accounting or disclosure, and the company responded with expanded disclosure and outreach to holders of 64% of shares [35]. Net: breeding-ground risk is low and dampening.

The 13-category shenanigans scorecard

Every category in the taxonomy, ranked so a PM sees in 20 seconds where the live items are (EM6 and CF4) and where the tests pass cleanly.

Sources: FY2021–FY2025 10-K reserve roll-forwards and cash-flow statements [36]; [37]; 2026 Proxy reconciliation and covenant note [38]; [39].

What to underwrite next

Five specific, named items decide whether this stays a footnote or becomes a valuation issue:

1. Prior-year development sign and size in FY2026 10-Qs (Note 10). The grade hinges here. A return to modest favorable development confirms reserves are adequate; repeated unfavorable development — especially beyond Marketplace — would re-grade Molina to Elevated/High, because it would mean 2023–2025 reserves were genuinely deficient, not merely de-cushioned [40].
2. Marketplace MCR trajectory. With MCR at 90.6% and reliant on ConnectiCare repricing and Special-Enrollment acuity, track whether 2026 pricing actions pull it back toward target — and whether a premium-deficiency reserve is established on any segment [41].
3. The "amounts due government agencies" line and CFO. After −$591 million in 2025, watch whether this normalizes; durable, repeatable CFO (not a float swing) is the upgrade signal [42].
4. Interest-coverage covenant headroom. The temporary cut to 1.75× expires through 2027; an actual breach or further amendment would be a real downgrade trigger [43].
5. Non-GAAP discipline. Confirm that future "acquisition-related" and impairment add-backs stay small relative to revenue and do not expand the GAAP-to-adjusted gap structurally [44].

Decisive read: the accounting risk here is a valuation-and-modeling haircut, not a thesis breaker. Nothing in the record points to misstatement, and governance and controls are genuinely strong. But two things should change how a PM models Molina: stop treating 2022–2024 margins as a clean run-rate (they carried a reserve tailwind that is gone), and stop treating operating cash flow as cash earnings (it is government-settlement float). Size the position to a business whose true normalized margin is lower and whose cash conversion is lumpier than the headline five-year averages suggest — and keep the FY2026 reserve-development line on a short leash.